By using bispecific antibodies targeting a tumor-associated antigen (TAA) on the cancer cells, and CD3 on the T-cells, it is possible to redirect and activate any circulating T-cells against tumor cells independently of the specificity of their TCR. Thanks to the bridging action of such TAAxCD3 bsAb, T-cells are brought in close proximity of the target cancer cells, leading to subsequent T-cell activation and T-cell–mediated killing of the tumor cells.
For more information on T-cell redirecting κλ-bodies, please visit Light Chain Bioscience.
Read our latest news
Next upcoming event
Next product launch - 26.06.2023
17 new scientific publications featuring Nanolive technology
Since the start of the year, 17 more papers have been published using Nanolive imaging, featuring an incredibly broad range of cell types; stem cells, adipocytes, neurons, osteoblasts, neutrophils, melanocytes, e. coli, primary synoviocytes, and several cancer cell...
Nanolive imaging confirms success of mesoestetic’s new treatment at the subcellular level
We are happy to see that Nanolive imaging has been used to confirm the success of another new therapy, this time treating melasma. In their latest paper “Depigmenting topical therapy based on a synergistic combination of compounds targeting the key pathways involved...
3D CELL EXPLORER
Budget-friendly, easy-to-use, compact solution for high quality non-invasive 4D live cell imaging
3D CELL EXPLORER-fluo
Multimodal Complete Solution: combine high quality non-invasive 4D live cell imaging with fluorescence
Automated live cell imaging: a unique walk-away solution for long-term live cell imaging of single cells and cell populations